Up-to-date guidance for the treatment of hepatitis C virus (HCV) infection is now available for healthcare providers from HCVguidelines.org, a new online resource launched this week by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA), in collaboration with the International Antiviral Society-USA (IAS-USA).
These guidelines are important tools in our shared national efforts to achieve the goals of the Action Plan for the Prevention, Care and Treatment of Viral Hepatitis, particularly its priorities of educating providers and improving testing, care, and treatment of viral hepatitis.
The HCV treatment arena is evolving quite rapidly with a number of new medications having been approved by the FDA in recent years (see related posts here and here) and more in development. Not only have these new treatments demonstrated improved cure rates, they are also better tolerated by patients and in many instances require a shorter period of treatment. This will likely result in increases in the number of people living with previously diagnosed HCV infections – including those for whom prior treatments were not successful – who are motivated to seek these new, improved treatments. The developers of these guidelines note the rapid pace of drug development has left many medical providers – as well as insurance companies – unsure what the optimal treatments are. The guidance provided through HCVguidelines.org will assist clinicians in delivering the most up-to-date care for their patients living with chronic HCV infection. –